Blog service

Highlights from Zacks analyst blog: Apple, Abbott Laboratories, Infosys, General Motors and NIO

For immediate release

Chicago, IL – December 30, 2021 – announces the list of stocks featured on the Analysts Blog. Every day, Zacks Equity Research analysts discuss the latest news and events impacting stocks and financial markets. Stocks recently featured on the blog include: Apple Inc. AAPL, Abbott Laboratories ABT, Infosys Limited INFY, General Motors Company GM, and NIO Inc. NIO.

Here are highlights from Wednesday’s analyst blog:

Best Stock Reports for Apple, Abbott and Infosys

Zacks Research Daily features the best research results from our team of analysts. Today’s Research Daily features new research reports on 16 major stocks, including Apple, Abbott Laboratories and Infosys. These research reports were handpicked from over 70 reports released today by our team of analysts.

You can see all today’s research reports here >>>

Actions of Apple outperformed the S&P 500 over the past year (+ 34.9% vs. + 30.4%), with the company benefiting from the momentum of its Services business, increased adoption of Apple Pay and a steadily growing subscriber base at Apple Music.

Although Apple’s business mostly revolves around iPhones, the service portfolio has become its new cash cow. However, supply chain constraints from silicon shortages and COVID-related manufacturing disruptions are the main headwinds for AAPL. The uncertainties related to the pandemic have also forced Apple to provide no indication for the first quarter of fiscal 2022.

(You can read the full research report on Apple here >>>)

Abbott stocks are up + 30.2% during the year-to-date period compared to a -2.5% loss for Zacks’ medical products industry. The Zacks analyst believes that Abbott’s branded generics and international diabetes business is expected to drive growth in the coming quarters. New product launches and acquisitions are other major catalysts.

During the third quarter of 2021, Abbott delivered organic sales growth in each of its operating segments, with the exception of neuromodulation. In adult nutrition, he reported strong global demand for Ensure and Glucerna. Diabetes Care sales were strong thanks to the strong global adoption of FreeStyle Libre. A difficult business environment, especially in China, should weigh on Abbott’s sales, however.

(You can read the full research report on Abbott here >>>)

Actions of Infosys gained + 14.8% in the past three months against Zacks’ IT services industry gain of + 1.4%. Zacks analyst believes that Infosys has benefited from large contracts and rapidly growing digital services.

Infosys’ focus on core Agile Digital and artificial intelligence-based services is another tailwind. Strong demand for its cloud, Internet of Things, cybersecurity, data and analytics services is a key enabler. The rise of anti-outsourcing sentiment in some countries, the high costs of subcontractors as well as the revision of its remuneration with variable remuneration and higher incentives, however weighed on the margins.

(You can read the full research report on Infosys here >>>)

Other noteworthy reports we feature today include General Motors and NIO.

Media contact

Zacks investment research

800-767-3771 ext 9339

[email protected]

Past performance is no guarantee of future results. The potential for loss is inherent in any investment. This material is provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold any security. No recommendation or advice is given as to whether an investment is suitable for a particular investor. It should not be assumed that any investment in any identified and described securities, companies, sectors or markets was or will be profitable. All information is current as of the date hereof and is subject to change without notice. The views or opinions expressed may not reflect those of the company as a whole. Zacks Investment Research does not engage in investment banking, market making or securities asset management activities. These returns come from hypothetical portfolios composed of stocks with a Zacks rank = 1 that have been rebalanced monthly without any transaction costs. These are not the returns of actual equity portfolios. The S&P 500 is an unmanaged index. Visit for more information on the performance numbers displayed in this press release.

Bitcoin, like the internet itself, could change everything

Blockchain and cryptocurrency have sparked one of the most exciting talking points in a generation. Some call it the “Internet of Money” and predict that it could change the way money works forever. If this is true, it could do to banks what Netflix did to Blockbuster and Amazon to Sears. Experts agree that we are in the early stages of this technology and as it develops it will create several investment opportunities.

Zacks just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and other cryptocurrencies with much less volatility than buying them directly.

See 3 Crypto Related Stocks Now >>

Click to get this free report

Abbott Laboratories (ABT): Free Stock Analysis Report

Apple Inc. (AAPL): Free Stock Analysis Report

Infosys Limited (INFY): Free Stock Analysis Report

General Motors Company (GM): Free Inventory Analysis Report

NIO Inc. (NIO): Free Stock Analysis Report

To read this article on, click here.

Zacks investment research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.